AU3760400A - Methods and reagents for the diagnosis and treatment of multiple sclerosis - Google Patents

Methods and reagents for the diagnosis and treatment of multiple sclerosis

Info

Publication number
AU3760400A
AU3760400A AU37604/00A AU3760400A AU3760400A AU 3760400 A AU3760400 A AU 3760400A AU 37604/00 A AU37604/00 A AU 37604/00A AU 3760400 A AU3760400 A AU 3760400A AU 3760400 A AU3760400 A AU 3760400A
Authority
AU
Australia
Prior art keywords
reagents
diagnosis
treatment
methods
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37604/00A
Inventor
Jason D. Bannan
Asa Ljunggren-Rose
William M. Mitchell
Subramaniam Sriram
Charles W. Stratton
Song-Yi Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU3760400A publication Critical patent/AU3760400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU37604/00A 1999-03-19 2000-03-17 Methods and reagents for the diagnosis and treatment of multiple sclerosis Abandoned AU3760400A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12559899P 1999-03-19 1999-03-19
US60125598 1999-03-19
US17678400P 2000-01-18 2000-01-18
US17694000P 2000-01-18 2000-01-18
US17666200P 2000-01-18 2000-01-18
US60176784 2000-01-18
US60176940 2000-01-18
US60176662 2000-01-18
PCT/US2000/007226 WO2000057187A2 (en) 1999-03-19 2000-03-17 Diagnosis and treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
AU3760400A true AU3760400A (en) 2000-10-09

Family

ID=27494587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37604/00A Abandoned AU3760400A (en) 1999-03-19 2000-03-17 Methods and reagents for the diagnosis and treatment of multiple sclerosis

Country Status (3)

Country Link
EP (1) EP1166117A2 (en)
AU (1) AU3760400A (en)
WO (1) WO2000057187A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555543B2 (en) 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP2329826A1 (en) * 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of multiple sclerosis
JP4674317B2 (en) * 2002-10-02 2011-04-20 ディエムアイ アクイジション コーポレイション Disease determination and monitoring
KR20150080004A (en) 2003-05-15 2015-07-08 앰피오 파마슈티컬스 인코퍼레이티드 Treatment of t-cell mediated diseases
JP5856843B2 (en) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド Pharmaceutical composition using diketopiperazine
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
WO2013055734A1 (en) 2011-10-10 2013-04-18 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
MX355446B (en) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Treatment of rhinitis.
EP2968315B1 (en) 2013-03-15 2020-06-03 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN109453165B (en) * 2018-10-16 2021-02-05 丹诺医药(苏州）有限公司 Solid dispersion of rifamycin-nitroimidazole coupled molecule and application thereof
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2134292A1 (en) * 1971-04-30 1972-12-08 Inst Nat Sante Rech Med Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
IE65771B1 (en) * 1990-01-25 1995-11-15 Zeneca Ltd Amplification of nucleotide sequences using vectorette units
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
EP0648121B1 (en) * 1993-05-05 1996-10-02 Palo Alto Medical Foundation Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis
CN1069196C (en) * 1996-02-09 2001-08-08 王成武 Application of rifampicin in linxiao'an medicine for treating gonorrhea
AU4151697A (en) * 1996-08-14 1998-03-06 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
ES2293678T3 (en) * 1997-05-06 2008-03-16 Vanderbilt University COMPOSITIONS OF ANTI-CLAMID AGENTS FOR DIAGNOSIS AND INFECTION TREATMENT CAUSED BY CLAMIDIAS.
CN1190581A (en) * 1998-02-25 1998-08-19 高绪侠 Complex rifampin injection
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease

Also Published As

Publication number Publication date
WO2000057187A9 (en) 2001-10-25
WO2000057187A3 (en) 2001-04-19
WO2000057187A2 (en) 2000-09-28
EP1166117A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
AU2815900A (en) Clinical and diagnostic database
AU4690699A (en) Apparatus and methods for entering cavities of the body
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
EP1144639A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
AU5116100A (en) Connector and method of use of the connector
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU6366100A (en) Novel methods and reagents for the treatment of osteoarthritis
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU1820499A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU2566201A (en) Compounds and methods for the treatment of pain
AU2001287007A1 (en) Reagents and methods for the diagnosis of cmv dissemination
AU8580598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786798A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
AU6509698A (en) Methods for clinical diagnosis
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase